The National Health Service (NHS), a mainstream healthcare services provider based in the United Kingdom, could soon be backing a cannabis product that is currently helping patients deal with PTSD, acne, anxiety and inflammation. Called the MediPen, the CBD vaporizer has been flying off the shelves in the past year.
“We’ve recently been working very closely with a team of NHS production and regulatory support pharmacists who’ve been able to meticulously analyze our proprietary formulation for both safety and cannabinoid concentration,” said managing director Jordan Owen.
The portable vaporizer is designed to be used on the go. It takes on a very slim, discreet profile with a clear, yellowish oil cartridge. Inside the pen, one can find CBD, or the non-psychoactive compound of marijuana (there is no THC in the company’s proprietary CBD formula). Patients who have tried the pen claim that the product works very well and provides instant relief for a number of everyday ailments. An individual suffering from depression highlighted that it helped him stay calm and relaxed.
The leading biotech company responsible for the product (also called MediPen), incorporates high quality CBD oil with pharmaceutical grade coconut oil to create a smooth vaping experience. The oil used for the pen originates from potent CBD strains (up to 20 percent) that are grown in the Netherlands. Unlike other CBD concentrates available in the market, MediPen only uses the best parts of the plant during extraction. By comparison, some manufacturers rely on trimmings, stalks and seeds- or less potent components of the plant. Using vortex mixing technology, MediPen scientists blend both oils (CBD and coconut) together to create a unified concentrate.
Looking into the Future
The vaporizer is being sold in cannabis shops for an estimated $65 (or £50). During an interview with The Independent, the company responsible for the MediPen mentioned that it is in talks with a group of pharmacists from the NHS. The representatives are from regulatory support, and could be helping the business navigate the legal minefield surrounding medical cannabis. Additionally, the NHS group also deals with the production side of development, which suggests that the company could be interested in pushing the pen out to more stores in the area.
So far, the business has been testing their unique marijuana oil formula with the NHS. For now, the NHS is unable to release information surrounding their experience with MediPen due to a non-disclosure agreement. The organization is expected to release a report that covers the testing process. The timely report could be used by other businesses that want to release a mainstream cannabis product.
“As the first consumer cannabis product to be tested by the NHS, we are confident that this will go a long way towards creating a properly regulated cannabis market in the UK and are extremely excited to see what the future holds,” said a MediPen representative.